KBC Group’s Immunovant IMVT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$134K Hold
3,490
﹤0.01% 1237
2026
Q1
$87K Hold
3,490
﹤0.01% 1408
2025
Q4
$89K Hold
3,490
﹤0.01% 1362
2025
Q3
$56K Buy
3,490
+1,683
+93% +$27.2K ﹤0.01% 1607
2025
Q2
$29K Sell
1,807
-1,735
-49% -$26.2K ﹤0.01% 1702
2025
Q1
$61K Buy
3,542
+443
+14% +$9.27K ﹤0.01% 1728
2024
Q4
$77K Buy
3,099
+1,163
+60% +$33K ﹤0.01% 1693
2024
Q3
$55K Buy
1,936
+612
+46% +$18.1K ﹤0.01% 1664
2024
Q2
$35K Hold
1,324
﹤0.01% 1779
2024
Q1
$43K Hold
1,324
﹤0.01% 1632
2023
Q4
$56K Buy
1,324
+406
+44% +$14.9K ﹤0.01% 1443
2023
Q3
$35K Buy
+918
New +$20.8K ﹤0.01% 1706

Other funds holding IMVT

KBC Group's IMVT Position: Q2 2026 in Review

KBC Group held its Immunovant (IMVT) position steady in Q2 2026 at 3,490 shares worth $134K. The position accounts for ﹤0.01% of the portfolio, ranked #1237.

KBC Group first reported a position in IMVT in Q3 2023 and has held it in 12 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • KBC Group held 3,490 shares of Immunovant worth $134K as of Q2 2026.
  • KBC Group left its Immunovant share count unchanged in Q2 2026.
  • Immunovant made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1237 holding.
  • KBC Group first reported a position in Immunovant in Q3 2023 and has held it in 12 quarters since.
  • 226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.